BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M

BIOLIFE SOLUTIONS INC

2025-FY EPS reported -$0.10 revenue$96,214,000

Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).
2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.
Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.
Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.